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Abstract. The demography of renal replacement therapy up
until the close of 1984 in Europe is presented, based on
return of individual patient questionnaires to the EDTA
Registry. These were completed by 84.7% of known centres
in 33 countries. Of 187 267 individually registered patients,
102 276 were known to be alive on defined forms of renal
replacement therapy on 31 December 1984. The stock of
patients alive on treatment by dialysis and transplantation
in Europe continued to grow and exceeded 200 per million
population in 14 European countries at the end of 1984.
During the same year, 21 198 new patients were accepted
for treatment in Europe, and crude acceptance rates for new
patients exceeded 60 per million population in four coun-
tries. Acceptance rates for elderly patients continued to
increase and age specific acceptance rates for males aged 65
and over exceeded 100 per million population in 12 coun-
tries. A total of 6802 renal transplants were reported during
1984. Regrafting accounted for a higher proportion of
transplants in Nordic countries and in the United King-
dom, compared with other nations. During 1984 the total
number of transplants reported to the Registry passed
50 000. The distribution of primary renal disease amongst
adult patients commencing treatment in 1984 is presented.
Amongst elderly patients commencing treatment, a
strikingly high proportion have chronic renal failure of
uncertain aetiology. Finally, causes of death have been
analysed amongst adult patients dying during 1984, show-
ing myocardial ischaemia and infarction to be the leading
cause of mortality.
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Introduction: timing of this report
This is the first report prepared by the Registry of the
European Dialysis and Transplant Association—European
Renal Association (EDTA Registry) for the new journal of
the Association. In the past, a series of 15 Combined
Reports on Regular Dialysis and Transplantation in
Europe have been published in the Proceedings of the
Association, the final one appearing in 1985 [1]. This Report
is based entirely on analyses of individual patient question-
naires reporting treatment up till 31 December 1984. These
analyses were carried out at the time of the mailing of the
1985 patient questionnaires, when the Registry's files are in
their best form for the year.
Methods: the Registry data base
The Registry collects its data from two sources, a centre
questionnaire and an individual patient questionnaire. New
centres are notified by their directors, or by the National
Keymen, who accept responsibility for maintaining a com-
plete list of units and trying to ensure as full a return of
questionnaires as possible. The contents of the centre ques-
tionnaire vary slightly from year to year, but it is designed
to obtain summary information on numbers of patients
treated during the year, and on centre practices. An indivi-
dual patient questionnaire is completed for every subject
accepted for renal replacement therapy. The information
requested includes personal patient details (name, sex and
date of birth), details of primary renal disease leading to
end-stage renal failure, dates and types of treatment, and
where appropriate, graft details, dialysis schedules, malig-
nancies diagnosed and causes of death. The primary renal
diseases and causes of death are reported by number codes
given in an instruction sheet which accompanies the patient
questionnaires. All patient questionnaires are printed in
English, but the instruction sheets are available in five lan-
guages. Once a patient has been reported to the Registry,
the information provided is preprinted on the patient
questionnaire, so the responding centre need only update
the record.
Demographic data on the number of patients accepted
for treatment and total numbers alive on therapy are avail-
able from both the centre and individual patient question-
naires. The Registry publishes figures from both sources,
and there may be differences. This is due not only to incom-
plete registration of individual patients, but also to double
reporting through the centre questionnaires where more
than one centre may claim responsibility for the care of
individual patients.
The data base is maintained on the Registry's dedicated
computer (VAX 11/750), and flexible analytical pro-
grammes have been developed in order to perform regular
demographic analyses and particular research projects.
Report from the EDTA Registry
Results: demographic statistics
The completeness of returns for the 1984 patient question-
naire are shown in Table 1. This shows the number of
known centres in each of the 33 countries reporting to the
Registry and the proportion which returned 1984 patient
questionnaires. Questionnaires were received from 1613 or
84.7% of centres in 33 countries. Complete returns were
received from 11 countries and from over 90% of known
centres in 21 countries. The proportion of responding
centres was less than 75% in only five countries. The
response rate was similar to that in previous years (2).
Table 2 shows the stock of patients of all ages known to
be alive on 31 December 1984 according to method of
treatment. Figures are given by country and, so that
programmes in various countries may be compared, the
total of all live patients is expressed per million population.
The stock of patients alive on treatment varied greatly from
Table 1. Summary of centres known to the Registry in 1984 in individual
countries. Absolute numbers, numbers per million population (PMP) and
the proportion (%) returning patient questionnaires are given
Country
Algeria
Austria
Belgium
Bulgaria
Cyprus
Czechoslovakia
Denmark
Egypt
Fed. Rep. Germany
Finland
France
German Dem. Rep.
Greece
Hungary
Iceland
Ireland
Israel
Italy
Lebanon
Libya
Luxembourg
Morocco
Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Tunisia
Turkey
United Kingdom
Yugoslavia
Total Registry
Population
in
millions
18.3
7.5
9.8
8.9
0.5
15.3
5.1
41.0
61.7
4.8
53.7
16.7
9.7
10.7
0.2
3.3
3.9
56.7
2.7
2.9
0.4
20.9
14.2
4.1
35.6
9.9
37.1
8.3
6.4
6.2
44.2
56.3
22.3
599.3
Known
centres
4
26
59
32
2
25
11
31
325
26
212
54
52
12
1
5
26
387
7
3
5
1
48
18
51
39
198
33
36
10
16
65
84
1904
Known
centres,
PMP
0.2
3.5
6.0
3.6
4.0
1.6
2.2
0.8
5.3
5.4
4.0
3.2
5.4
1.1
5.0
1.5
6.7
6.8
2.6
1.0
12.5
0.1
3.4
4.4
1.4
3.9
5.3
4.0
5.6
1.6
0.4
1.2
3.8
3.3
% Replied
75.0
100.0
91.5
93.8
100.0
100.0
90.9
90.3
87.1
100.0
86.3
98.2
69.2
100.0
100.0
80.0
100.0
68.5
14.3
33.3
100.0
100.0
79.2
94.4
98.0
74.4
93.4
100.0
91.7
100.0
87.5
93.9
81.0
84.7
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Table 2. Stock of patients alive on 31 December 1984 in individual countries. Numbers on different forms of renal
replacement therapy given together with total per million population
Country
Algeria
Austria
Belgium
Bulgaria
Cyprus
Czechoslovakia
Denmark
Egypt
Fed. Rep. Germany
Finland
France
German Dem. Rep.
Greece
Hungary
Iceland
Ireland
Israel
Italy
Lebanon
Libya
Luxembourg
Morocco
Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Tunisia
Turkey
United Kingdom
Yugoslavia
Hosp. HD
81
1172
2003
720
95
823
380
754
14 755
245
8892
1426
1184
355
21
155
823
11347
11
50
81
48
1548
224
855
1560
7878
754
826
225
415
1744
2572
Home HD
1
54
107
23
0
2
44
2
177S
3
1807
0
1
0
0
26
46
820
0
0
4
0
126
4
0
0
316 .
99
164
0
1
2006
16
IPD
0
1
6
0
0
9
34
31
186
10
136
4
4
25
0
7
48
139
0
0
0
0
1
3
43
2
91
27
4
1
10
68
8
CAPD
14
18
145
1
0
5
164
10
326
135
813
6
168
8
0
49
132
1057
0
0
0
0
265
20
11
8
596
185
200
17
18
1859
24
With
funct.
graft
11
406
1120
5
34
254
430
74
3057
583
3868
503
244
122
8
249
276
1585
1
9
7
9
499
639
283
104
1812
1220
604
7
128
5299
205
Total
107
1651
3381
749
129
1093
1052
871
20099
976
15 516
1939
1601
510
29
486
1325
14948
12
59
92
57
2439
890
1192
1674
10 693
2285
1798
250
572
10976
2825
Per
million
pop.
5.8
220.1
345.0
84.2
258.0
71.4
206.3
21.2
325.8
203.3
288.9
116.1
165.1
47.7
145.0
147.3
339.7
263.6
4.4
20.3
230.0
2.7
171.8
217.1
33.5
169.1
288.2
275.3
280.9
40.3
12.9
195.0
126.7
country to country, but exceeded 250 per million popu-
lation in nine nations. The figure was highest in Belgium,
where there were 345 patients alive on renal replacement
therapy per million population at the end of 1984. The table
does not include patients previously reported to the Registry
but not updated for 1984.
The numbers of new male and female patients accepted
for first treatment during 1984 are shown in Table 3, which
gives the crude acceptance rate per million population by
country. Over 60 new patients per million population were
accepted onto treatment during 1984 in Austria, Belgium,
the Federal Republic of Germany and Israel. Between 50
and 60 new patients per million population were taken on in
Iceland, Norway, Spain and Sweden. The total column of
the table includes patients whose sex was not recorded.
Acceptance rates for new patients in 1984 are shown separ-
ately for males and females in Tables 4 and 5, broken down
into four age groups. The take-on rates are expressed as age
and sex specific; in other words, calculated in relation to the
total number of people in the general population of the
corresponding age and sex group. Data on population were
obtained from the WHO Statistics Annual using the most
up to date information available for each country. In coun-
tries with the highest overall acceptance rates such as
Belgium and the Federal Republic of Germany, take-on
rates for males increased with age so that the highest
acceptance rates were in the 65 and over age group. In these
countries, the same pattern was not observed among
females. Acceptance rates for women aged 65 and over are
similar to those for women aged between 35 and 64 at first
treatment. In countries such as the United Kingdom and
the German Democratic Republic with an overall accept-
ance rate of between 30 and 35 per million population, age
specific acceptance rates fell in the 65 and over age group,
whether patients were male or female.
Transplantation activity during 1984 is summarised for
individual countries in Table 6. This shows grafts according
to source, live donor or cadaver, and gives the numbers
which were first, second, third or fourth grafts. The table
gives the total number of grafts done in each country during
1984 and this will include transplants whose source was
unknown. The grafts are given according to the country
Table 3. Numbers of new patients accepted onto renal replacement therapy
in 1984 by country. Males and females shown separately. The total
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Table 4. Age specific acceptance rate for male patients onto renal
replacement therapy in 1984 shown by individual country
per million population (PMP) is also given
Country
Algeria
Austria
Belgium
Bulgaria
Cyprus
Czechoslovakia
Denmark
Egypt
Fed. Rep. Germany
Finland
France
German Dem. Rep.
Greece
Hungary
Iceland
Ireland
Israel
Italy
Lebanon
Libya
Luxembourg
Morocco
Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Tunisia
Turkey
United Kingdom
Yugoslavia
New patients 1984
Male
24
241
354
112
10
193
113
278
2273
100
1433
304
273
75
4
59
182
1573
0
10
9
0
271
128
236
265
1289
301
179
47
190
1149
446
Female
27
215
322
62
9
123
90
124
1833
64
999
237
176
76
6
33
102
1125
0
8
6
0
214
90
159
157
872
193
117
39
110
753
354
Total
51
464
683
175
20
316
205
411
4142
167
2644
544
451
152
10
92
290
2738
0
18
15
0
487
218
395
426
2179
497
300
87
303
1910
808
Acceptance
rate
PMP
2.8
61.9
69.7
19.7
40.0
20.7
40.2
10.0
67.1
34.8
49.2
32.6
46.5
14.2
50.0
27.9
74.4
48.3
0
6.2
37.5
0
34.3
53.2
11.1
43.0
58.7
59.9
46.9
14.0
6.9
33.9
36.2
Country
Algeria
Austria
Belgium
Bulgaria
Cyprus
Czechoslovakia
Denmark
Egypt
Fed. Rep. Germany
Finland
France
German Dem. Rep.
Greece
Hungary
Iceland
Ireland
Israel
Italy
Lebanon
Libya
Luxembourg
Morocco
Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Tunisia
Turkey
United Kingdom
Yugoslavia
Age specific acceptance, 1984,
per million population
0-14
1.0
3.9
13.7
2.0
0
1.6
7.5
0.1
4.0
8.1
7.5
4.7
3.6
3.3
0
7.7
5.6
4.0
0
0
0
0
5.7
6.6
2.0
1.4
7.2
3.7
3.2
0
0.1
6.7
3.2
15-34
6.0
36.2
38.8
16.1
8.8
19.8
34.0
11.1
28.3
21.7
30.0
34.6
29.3
15.2
23.8
31.0
53.4
27.3
0
25.8
17.2
0
19.8
35.9
17.7
35.4
49.8
43.0
22.3
18.1
13.9
30.1
27.9
35-64
8.3
128.5
114.7
53.1
70.3
57.5
68.6
35.7
132.3
88.5
89.9
74.3
99.1
23.5
90.9
78.9
210.8
93.9
0
14.9
75.8
0
68.1
97.8
21.9
106.7
129.8
104.9
105.9
50.0
19.4
73.7
85.5
males
65 and over
4.0
97.3
156.6
4.2
104.2
6.6
67.1
34.7
155.7
43.5
121.8
8.6
106.8
7.1
0
12.4
284.8
133.1
0
0
150.0
0
81.1
139.0
0.7
148.1
120.2
150.1
99.2
36.0
8.3
51.8
30.6
where the patient is registered and this does not necessarily
correspond to place of grafting. During 1984, no fifth or
numerically higher grafts were reported.
The instruction sheet which accompanies the patient
questionnaire affords 55 choices of primary renal disease.
Some of these have been amalgamated in Table 7, which
shows the proportional distribution of primary renal
diseases among patients commencing therapy in 1984
according to age at start of treatment. There were 15 783
patients aged between 15 and 64 at start of therapy in 1984
for whom primary renal disease was provided and an
additional 4011 aged 65 and over. In the 15 to 64-year old
group glomerulonephritis accounted for 28.3% of primary
renal diseases and pyelonephritis/interstitial nephritis for a
further 17.1%. Amongst patients aged 65 and over, a
striking observation is the proportion (21.1%) of patients
with primary renal disease given as chronic renal failure,
aetiology uncertain.
In Table 8 the proportional distribution of causes of
death amongst patients dying in 1984 is given according to
age at death. Information was available on a total of 8612
patients who died aged 15 and over during 1984. The most
common single cause of death in the two age groups
shown is myocardial ischaemia and infarction, followed by
cerebrovascular accident.
Discussion
Completeness of returns to the EDTA Registry
The data given in this paper are entirely based on analyses
of the file of individually registered patients. The EDTA
Registry now holds 187 267 such records. Of the 1904
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Table 5. Age specific acceptance rate for female patients onto renal
replacement therapy in 1984 shown by individual country
Country
Algeria
Austria
Belgium
Bulgaria
Cyprus
Czechoslovakia
Denmark
Egypt
Fed. Rep. Germany
Finland
France
German Dem. Rep.
Greece
Hungary
Iceland
Ireland
Israel
Italy
Lebanon
Libya
Luxembourg
Morocco
Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Tunisia
Turkey
United Kingdom
Yugoslavia
Age specific acceptance, 1984,
per million population
0-14
1.4
5.4
12.3
1.0
0
0.6
5.9
0.5
4.4
2.1
8.0
6.7
0.9
0.9
33.3
4.0
11.2
4.1
0
0
0
0
6.6
4.6
2.8
5.2
6.7
6.4
6.7
0.8
0.3
4.0
1.1
15-34
4.0
27.6
27.4
10.3
9.3
13.3
14.5
6.1
22.5
14.0
17.3
24.4
22.0
14.5
25.6
22.2
25.1
14.9
0
19.8
17.9
0
12.7
24.8
11.7
23.1
27.9
19.0
12.3
15.5
6.9
12.4
18.7
35-64
12.6
98.2
106.2
28.7
66.4
35.6
72.2
14.6
88.5
57.0
59.3
60.0
55.5
24.8
93.8
41.2
102.0
62.4
0
16.4
44.8
0
48.6
80.0
12.7
• 47.6
88.2
79.2
67.6
37.0
13.2
51.3
66.6
females
65 and over
3.6
62.9
102.6
0
59.3
0
25.5
11.9
92.7
10.9
62.5
2.3
61.7
3.6
76.9
5.1
158.2
77.7
0
0
66.7
0
62.3
53.8
0.9
54.3
54.5
61.9
41.7
10.9
3.1
21.7
20.6
known units in 33 countries, 84% returned patient ques-
tionnaires for 1984. In some countries the returns were com-
plete and in most they were in excess of 80%. Despite the
growing number of units providing dialysis and transplant
facilities in Europe, compliance in returning EDTA forms
has been maintained.
Trends in renal replacement therapy
At the close of 1984 there were 102 276 patients individually
registered alive on defined methods of renal replacement
therapy in Europe. This represents an increase of 13.7%
compared with 31 December 1983 [1]. Patients alive on
hospital haemodialysis had increased by 11.8%, but those
treated on home haemodialysis had fallen by 5.2%. Home
haemodialysis appears to have been supplanted by con-
tinuous ambulatory peritoneal dialysis (CAPD). Numbers
on this form of therapy rose to 6254 in 1984, representing an
increase of 23.0%. The stock of patients alive on renal
replacement therapy at the close of 1984 exceeded 200 per
million population in 14 countries. This treatment figure was
surpassed by Austria, Denmark, Finland and Norway for
the first time during 1984 (Table 2).
Acceptance rates for new patients varied greatly from
country to country during 1984 (Table 3). Acceptance rates
were in excess of 60 per million population in four coun-
tries. In 16 countries acceptance rates remained below 35
per million population. Overall, 21 198 new patients were
accepted for renal replacement therapy in Europe during
1984, with a preponderance of males to females in the ratio
1.4:1.
The variation in acceptance policy between countries is
even more striking if age and sex specific acceptance rates
are compared (Tables 4, 5). In countries where facilities for
treatment of end-stage renal failure are restricted, it is the
oldest patients, in other words those aged 65 and over, who
are excluded from treatment. Even in nations with high
overall acceptance rates, there is still a discrepancy between
acceptance rates for elderly males and elderly females.
Take-on rate for males aged 65 and over was 150 per mil-
lion population or more in Belgium, the Federal Republic
of Germany, Israel, Luxembourg and Sweden. By compari-
son the age specific acceptance rate exceeded 150 per million
population for females in only one country.
The number of individually recorded renal transplants
performed in 1984 was 6802 (Table 6). Proportions of live
donors and of regrafting varied between countries. There
were high proportions of live donors in Egypt, Greece,
Ireland, Israel, Norway and Sweden, but low proportions in
Denmark, Switzerland and Eastern European countries.
Regrafting accounted for more of the grafts in Nordic coun-
tries and in the United Kingdom than in other nations
where fewer patients were transplanted. Patient question-
naires recorded 50 655 renal transplants performed in
Europe by 31 December 1984.
Analysis of primary renal diseases leading to end-stage
renal failure amongst adult patients commencing treatment
in 1984 showed that glomerulonephritis is still the most
common diagnosis. Amongst elderly patients, the aetiology
of chronic renal failure is unknown in one-fifth of cases
(Table 7). The increase in acceptance rates for elderly
patients has meant that diabetes, vascular and hypertensive
disease account for a greater proportion of primary renal
diseases diagnosed as leading to end-stage renal failure.
Cardiovascular disease remains the leading cause of death
amongst adult patients on renal replacement therapy (Table
8). Among patients aged 15-64 at time of death, cardiac
causes accounted for 40% of mortality. In the 65 and over
age group the figure was similar, at 37.6%.
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Table 6. Grafts reported to the Registry in 1984 by individual country. Grafts are shown according to source and number in overall graft sequence
Country
Algeria
Austria
Belgium
Bulgaria
Cyprus
Czechoslovakia
Denmark
Egypt
Fed. Rep. Germany
Finland
France
German Dem. Rep.
Greece
Hungary
Iceland
Ireland
Israel
Italy
Lebanon
Libya
Luxembourg
Morocco
Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Tunisia
Turkey
United Kingdom
Yugoslavia
Live donor
1st
0
3
36
0
7
1
6
40
34
9
30
4
15
1
0
16
17
25
0
4
I
0
3
51
1
1
50
60
2
1
13
89
35
2nd
0
0
0
0
0
0
1
1
2
1
4
1
0
0
0
2
0
0
0
0
0
0
2
4
0
0
2
2
0
0
0
10
1
3rd
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
4th
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total
0
3
36
0
7
1
7
41
36
10
35
5
15
1
0
19
17
25
0
4
1
0
5
56
1
1
52
62
2
1
13
100
36
Cadaver
1st
3
134
165
0
5
101
90
0
777
78
772
145
15
44
0
50
57
338
0
0
2
6
90
74
117
49
627
179
103
2
3
959
16
2nd
0
19
27
0
0
16
26
0
117
6
65
8
1
8
0
8
5
32
0
0
0
0
12
13
7
2
32
35
12
0
0
205
3
3rd
0
4
1
0
0
0
8
0
11
0
1
0
0
0
0
0
0
2
0
0
0
0
1
2
0
0
3
7
2
0
0
40
0
4th
0
1
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
4
0
Total
3
158
193
0
5
117
125
0
906
84
838
153
16
52
0
58
62
372
0
0
2
6
103
90
124
51
662
221
117
2
3
1208
19
All
grafts
3
165
233
0
12
122
139
43
1010
99
981
174
36
59
0
78
88
413
0
4
3
6
121
154
128
56
771
294
161
3
17
1369
60
Table 7. Proportional distribution (%) of causes of end-stage renal failure in patients starting renal replacement
therapy in 1984, according to age at start of therapy
Causes of end-stage renal failure
Chronic renal failure, aetiology uncertain
Glomerulonephritis—histologically not examined
—histologically examined
Pyelonephritis/interstitial nephritis—cause not specified
—associated with neurogenic bladder
—due to congenital obstructive uropathy
with or without vesico-ureteric reflux
—due to acquired obstructive uropathy
—due to vesico-ureteric reflux without
obstruction
—due to urolithiasis
—due to other cause
Nephropathy—caused by drugs or nephrotoxic agents—cause not specified
—due to analgesic drugs
Age at start
of renal replacement
therapy, 1984 (%)
15-64
12.8
17.1
11.2
9.1
0.5
1.2
1.4
1.6
2.3
1.0
0.5
2.8
65 and over
21.1
10.6
4.2
12.6
0.4
3.5
0.3
3.6
1.1
0.7
3.4 continued on next page
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Table 7 (continued)
Causes of end-stage renal failure
Cystic kidney disease—type unspecified
Polycystic kidneys—adult type
—infantile and juvenile types
Medullary cystic disease, including nephronophthisis
Hereditary/familial nephropathy
Hereditary nephritis with nerve deafness (Alport's syndrome)
Cystinosis
Oxalosis
Renal vascular disease—type unspecified
—due to malignant hypertension (no primary renal disease)
—due to hypertension (no primary renal disease)
—due to polyarteritis
Wegener's granulomatosis
Diabetes—insulin dependent (type I) .
—non-insulin dependent (type II)
Myelomatosis
Amyloid
Lupus erythematosus
Henoch-Schonlein purpura
Goodpasture's syndrome
Scleroderma
Haemolytic uraemic syndrome (Moschcowitz syndrome)
Multi-system disease—other
Cortical or tubular necrosis
Tuberculosis
Gout
Nephrocalcinosis and hypercalcaemic nephropathy
Balkan nephropathy
Kidney tumour
Traumatic or surgical loss of kidney
Other identified renal disorders
Age at start
of renal replacement
therapy, 198'
15-64- l
(%) 1
1.1
7.9
0.2
0.2
1.5
0.7
<0.1
0.1
1.8
2.1
4.0
0.2
0.2
7.8
2.4
0.6
1.8
1.0
0.3
0.3
0.1
0.2
0.3
0.3
0.8
0.6
0.2
0.7
0.4
0.2
t
55 and over
0.9
4.7
0.1
<0.1
0.2
<0.1
0
<0.1
4.2
1.0
7.5
0.6
0.1
5.6
4.7
1.7
1.8
0.1
cO.l
0.1
0.2
<0.1
0.2
0.5
1.0
0.9
0.1
0.2
0.5
0.1
0.6 0.8
Total patients with diagnosis available 15 783 4011
Table 8. Proportional distribution (%) of causes ofdeath in patients dying in 1984, according to age at death
Causes ofdeath on renal replacement therapy Age at death 1984
15-64 65 and over
Cause ofdeath uncertain/not determined/unknown
Cardiac: Myocardial ischaemia and infarction
Hyperkalaemia
Haemorrhagic pericarditis
Other causes of cardiac failure
Cardiac arrest, cause unknown
Hypertensive cardiac failure
Hypokalaemia
Fluid overload
6.0 7.1
13.3
2.7
1.1
7.2
9.9
3.5
0.3
2.2
13.6
1.3
0.3
9.4
10.1
1.9
<0.1
1.0 continued on next page
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Table 8 (continued)
Causes of death on renal replacement therapy Age at death 1984
15-64 65 and over
Vascular: Pulmonary embolus
Cerebrovascular accident
Haemorrhage from graft site
Haemorrhage from vascular access or dialysis circuit
Haemorrhage from ruptured vascular aneurysm
Haemorrhage from surgery
Other haemorrhage
Infection: Pulmonary infection (bacterial)
Pulmonary infection (viral)
Pulmonary infection (fungal)
Infections elsewhere
Septicaemia
Tuberculosis
Generalised viral infection
Peritonitis
Liver Disease: Viral hepatitis
Drug toxicity
Cirrhosis—not viral
Cystic liver disease
Liver failure—cause unknown
Gastro-intestinal: Gastro-intestinal haemorrhage
Mesenteric infarction
Pancreatitis
Sclerosing (or adhesive) peritoneal disease
Perforation of peptic ulcer
Perforation of colon
Social: Patient refused further treatment
Suicide
Therapy ceased for any other reason
Miscellaneous: Uraemia caused by graft failure
Bone marrow depression
Cachexia
Malignant disease
Dementia
Accident: Accident related to treatment
Accident unrelated to treatment
Other identified cause of death
1.2
10.4
0.2
0.2
0.8
0.3
0.7
3.0
0.5
0.3
0.8
8.1
0.6
0.4
1.7
1.2
0.1
0.8
0.1
0.5
2.1
0.7
0.9
0.4
0.2
0.5
0.7
0.7
0.7
0.3
0.1
2.9
5.4
1.1
0.4
0.8
1.0
11.7
<0.1
0.3
0.6
<0.1
0.3
3.3
0.4
0.2
0.4
4.5
0.4
<0.1
1.8
0.5
0.1
0.8
<0.1
0.1
1.7
0.8
0.2
0.3
0.3
0.6
1.8
0.4
1.5
0
0.3
9.3
6.2
1.7
0.2
0.5
4.0 3.1
Total patients with known cause of death 5917 2695
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